Comparison
Fisetin vs Noopept
Side-by-side of Fisetin and Noopept. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Fisetin
Fisetin is a flavonoid found in strawberries with senolytic activity in mouse models. Hickson 2019 confirmed senescent-cell clearance in human adipose tissue.
Noopept
Noopept cognitive enhancer profile: 10 to 30 mg dosage, dipeptide nootropic mechanism, memory effects, and how it compares to piracetam.
Effects at a glance
Fisetin
- •Flavonoid found in strawberries; most potent natural senolytic in screening assays (Yousefzadeh 2018)
- •Hickson 2019 confirmed reduced senescent-cell burden in human adipose tissue at 20 mg/kg pulsed for 2 days
- •Pulsed Mayo protocol (20 mg/kg/day x 2 days monthly) is the only dose with human biomarker evidence
- •Daily low-dose (100-500 mg) is mechanistically weaker but commonly used
- •Low oral bioavailability; with-fat dosing modestly improves absorption
- •Active cancer is a relative contraindication pending clearer polyphenol-treatment data
Noopept
- •Russian dipeptide nootropic developed in the 1990s, registered in Russia 2002 for cognitive impairment
- •Roughly 1,000-fold higher per-mg potency than piracetam; therapeutic dose 10 to 30 mg/day
- •Active metabolite cycloprolylglycine modulates AMPA receptors and increases NGF and BDNF in rodent hippocampus
- •Russian RCTs in stroke recovery and vascular cognitive impairment show modest improvements over 4 to 8 weeks
- •Western evidence base is essentially absent; healthy-adult enhancement trials have not been published
- •Unscheduled in the US but not approved for human consumption; UK is prescription-only since 2014
Side-by-side
| Attribute | Fisetin | Noopept |
|---|---|---|
| Category | supplement | nootropic |
| Also known as | 3,7,3',4'-tetrahydroxyflavone | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam |
| Half-life (hr) ↗ | 2 | 0.7 |
| Typical dose (mg) ↗ | 500 | 20 |
| Dosing frequency | pulsed 2 days/month (Mayo protocol) or daily continuous (empirical) | 2 to 3 times daily, last dose before mid-afternoon |
| Routes | oral | oral, sublingual |
| Onset (hr) | 1 | 0.5 |
| Peak (hr) | 4 | 1 |
| Molecular weight | 286.24 | 318.37 |
| Molecular formula | C15H10O6 | C17H22N2O4 |
| Mechanism | Senolytic via Bcl-2 family inhibition (Bcl-xL, Bcl-w); broad polyphenol with Nrf2 activation, mTOR inhibition at high concentrations, and antioxidant effects. | Hydrolyzed to active metabolite cycloprolylglycine; AMPA receptor modulation, BDNF and NGF upregulation, antioxidant and antiexcitotoxic effects. |
| Legal status | OTC dietary supplement | Approved in Russia and CIS states; prescription-only in UK; unscheduled and unapproved in US, EU varies |
| WADA status | allowed | unknown |
| DEA / Rx | OTC supplement | Not scheduled in the US |
| Pregnancy | Insufficient data | Not recommended |
| CAS | 528-48-3 | 157115-85-0 |
| PubChem CID | 5281614 | 183503 |
| Wikidata | Q230614 | Q4321022 |
Safety profile
Fisetin
Common side effects
- mild GI upset
- headache (rare)
Contraindications
- active cancer (theoretical, polyphenol interactions)
- pregnancy and lactation (insufficient data)
- concurrent CYP3A4-sensitive medications
Interactions
- statins (CYP3A4 substrates): theoretical reduction in statin clearance at high fisetin doses(minor)
- warfarin: theoretical CYP-mediated interaction; monitor INR if combining(moderate)
- other senolytics (rapamycin, dasatinib + quercetin): additive senolytic effect; pairing is investigational(minor)
Noopept
Common side effects
- headache
- irritability
- sleep disturbance with late-day dosing
- occasional blood pressure elevation
Contraindications
- pregnancy
- lactation
- pediatric use
- severe hepatic impairment
- severe renal impairment
Interactions
- memantine and other glutamatergic agents: theoretical AMPA-pathway interaction(minor)
- antidepressants: theoretical effect via BDNF axis, undocumented(minor)
- antihypertensives: occasional blood pressure elevation may require monitoring(minor)
Which Should You Take?
Fisetin comes out ahead for most readers on the criteria we weight: 2 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Noopept is the right call when one of the conditionals below applies.
- → If your priority is healthspan extension, pick Fisetin.
- → If your priority is memory, pick Noopept.
- → If your priority is stress and HPA-axis regulation, pick Noopept.
Edge case: If you want to avoid controlled substance, Fisetin is the more accessible choice.
Default choice: Fisetin. Lower friction to source, and broader goal coverage. Reach for Noopept only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Fisetin and Noopept?
Fisetin and Noopept differ in category (supplement vs nootropic), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Fisetin or Noopept?
Fisetin half-life is 2 hours; Noopept half-life is 0.7 hours.
Can you stack Fisetin with Noopept?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper